Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
Summary
Beyond Air reported strong fiscal 2026 results, with full-year revenue rising 107% to $7.7 million and fourth-quarter revenue increasing 66% year over year. The company highlighted customer retention above 90%, new hospital wins, and a national group purchasing agreement that broadens access to inhaled nitric oxide therapy. It also updated investors on the second-generation LungFit PH system, which remains under FDA review and could significantly expand the addressable market if approved. Beyond Air is also changing its fiscal year-end to December 31 and provided revenue guidance of $8 million for calendar 2026 and $16 million to $18 million for 2027.
Classifications
industries
Fintech & Banking
applications
Governance, risk and compliance
AI Classifications
Labels
Financial Technology
SaaS
Data Analytics Software
Linked Companies
Nasdaq
$5M to $10M